The Puzzle of Predicting Response to Immune Checkpoint Blockade

EBioMedicine. 2018 Jul:33:18-19. doi: 10.1016/j.ebiom.2018.06.020. Epub 2018 Jun 20.

Author

Mykola Onyshchenko¹

Affiliation

¹ Division of Hematology-Oncology, Department of Internal Medicine, David Geffen School of Medicine at the University of California Los Angeles, USA. Electronic address: monyshchenko@mednet.ucla.edu.

No abstract available

MeSH terms

Antineoplastic Agents, Immunological / therapeutic use
CTLA-4 Antigen / immunology
Humans
Immunotherapy*
Melanoma / immunology
Melanoma / therapy
Neoplasms / immunology*
Neoplasms / therapy
Programmed Cell Death 1 Receptor / immunology
Tumor Suppressor Protein p53 / genetics

Substances

Antineoplastic Agents, Immunological
CTLA-4 Antigen
Programmed Cell Death 1 Receptor
TP53 protein, human
Tumor Suppressor Protein p53